(VRTX) Vertex Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 113.007m USD | Total Return: -10.3% in 12m

Medicines, Therapies, Treatments, Pharmaceuticals

Total Rating 58

Safety 92

Buy Signal 0.06

Biotechnology
Industry Rotation: +1.7

Market Cap: 113B
Avg Turnover: 548M USD

ATR: 2.68%
Peers RS (IBD): 16.8

Risk 5d forecast

Volatility27.5%

Rel. Tail Risk-9.81%

Reward TTM

Sharpe Ratio-0.32

Alpha-29.63

Character TTM

Beta0.483

Beta Downside0.099

Drawdowns 3y

Max DD29.07%

CAGR/Max DD0.34

EPS (Earnings per Share)

EPS CAGR: 9.99%
EPS Trend: -1.5%

Last SUE: -0.02
Qual. Beats: 0

Revenue

Rev. CAGR: 12.18%
Rev. Trend: 98.4%

Last SUE: 1.27
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: VRTX Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotech firm that develops and markets transformative therapies for high-need specialty diseases, primarily cystic fibrosis (CF) and blood-disorder indications such as sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Its flagship CF portfolio includes TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, while its pipeline extends to CASGEVY (SCD/TDT), JOURNAVX (acute pain), and several mRNA or small-molecule programs targeting CF, kidney disease, type-1 diabetes, myotonic dystrophy and polycystic kidney disease.

In the most recent quarter (Q2 2024), Vertex reported revenue of $2.31 billion, up 18 % year-over-year, driven by continued growth of its CF franchise and early sales of CASGEVY. The company ended the quarter with $7.5 billion of cash, cash equivalents and marketable securities, and R&D spending reached $1.22 billion, reflecting its aggressive pipeline investment. Adjusted earnings per share came in at $1.45, beating consensus estimates.

Key sector drivers supporting Vertex’s outlook include the expanding global CF patient pool-estimated to exceed 100,000 individuals after universal newborn screening adoption-and sustained biotech capital inflows, with U.S. biotech IPO proceeds hitting a 12-month high of $12 billion in early 2024. Additionally, the FDA’s accelerated-approval pathways for gene-editing and mRNA therapeutics are expected to shorten time-to-market for Vertex’s next-generation candidates such as VX-522 and inaxaplin.

For a deeper dive into how these dynamics translate into valuation metrics, you might want to explore ValueRay’s analytical tools.

Headlines to Watch Out For

Cystic fibrosis drug sales drive revenue growth
Pipeline success in non-CF indications expands market
Regulatory approvals for new therapies impact stock
Competition in CF and gene editing therapies poses risk

Piotroski VR‑10 (Strict) 7.0

Net Income: 3.95b TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 16.56 > 1.0
NWC/Revenue: 60.97% < 20% (prev 54.75%; Δ 6.22% < -1%)
CFO/TA 0.14 > 3% & CFO 3.63b > Net Income 3.95b
Net Debt (-1.21b) to EBITDA (4.83b): -0.25 < 3
Current Ratio: 2.90 > 1.5 & < 3
Outstanding Shares: last quarter (256.1m) vs 12m ago -1.69% < -2%
Gross Margin: 86.28% > 18% (prev 0.86%; Δ 8.54k% > 0.5%)
Asset Turnover: 49.46% > 50% (prev 48.89%; Δ 0.57% > 0%)
Interest Coverage Ratio: 347.6 > 6 (EBITDA TTM 4.83b / Interest Expense TTM 13.3m)

Altman Z'' 6.71

A: 0.28 (Total Current Assets 11.20b - Total Current Liabilities 3.86b) / Total Assets 26.14b
B: 0.52 (Retained Earnings 13.56b / Total Assets 26.14b)
C: 0.19 (EBIT TTM 4.62b / Avg Total Assets 24.34b)
D: 1.81 (Book Value of Equity 13.55b / Total Liabilities 7.48b)
Altman-Z'' Score: 6.71 = AAA

Beneish M -2.82

DSRI: 1.17 (Receivables 2.05b/1.61b, Revenue 12.04b/11.02b)
GMI: 1.00 (GM 86.28% / 86.11%)
AQI: 0.99 (AQ_t 0.45 / AQ_t-1 0.46)
SGI: 1.09 (Revenue 12.04b / 11.02b)
TATA: 0.01 (NI 3.95b - CFO 3.63b) / TA 26.14b)
Beneish M-Score: -2.82 (Cap -4..+1) = A

What is the price of VRTX shares? As of April 17, 2026, the stock is trading at USD 435.65 with a total of 1,325,357 shares traded.
Over the past week, the price has changed by -2.49%, over one month by -6.53%, over three months by -1.29% and over the past year by -10.34%.

Is VRTX a buy, sell or hold? Vertex Pharmaceuticals has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy VRTX.

StrongBuy: 14
Buy: 4
Hold: 14
Sell: 1
StrongSell: 1

What are the forecasts/targets for the VRTX price?

Analysts Target Price	548.5	25.9%

Vertex Pharmaceuticals (VRTX) - Fundamental Data Overview as of 16 April 2026

P/E Trailing = 28.9811
P/E Forward = 23.0947
P/S = 9.4162
P/B = 5.9966
P/EG = 2.1486
Revenue TTM = 12.04b USD
EBIT TTM = 4.62b USD
EBITDA TTM = 4.83b USD
Long Term Debt = 2.03b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 82.8m USD (from shortTermDebt, last quarter)
Debt = 3.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.21b USD (from netDebt column, last quarter)
Enterprise Value = 110.28b USD (113.01b + Debt 3.88b - CCE 6.61b)
Interest Coverage Ratio = 347.6 (Ebit TTM 4.62b / Interest Expense TTM 13.3m)
EV/FCF = 34.53x (Enterprise Value 110.28b / FCF TTM 3.19b)
FCF Yield = 2.90% (FCF TTM 3.19b / Enterprise Value 110.28b)
FCF Margin = 26.53% (FCF TTM 3.19b / Revenue TTM 12.04b)
Net Margin = 32.84% (Net Income TTM 3.95b / Revenue TTM 12.04b)
Gross Margin = 86.28% ((Revenue TTM 12.04b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 85.56% (prev 86.52%)
Tobins Q-Ratio = 4.22 (Enterprise Value 110.28b / Total Assets 26.14b)
Interest Expense / Debt = 0.08% (Interest Expense 3.30m / Debt 3.88b)
Taxrate = 10.51% (139.9m / 1.33b)
NOPAT = 4.14b (EBIT 4.62b * (1 - 10.51%))
Current Ratio = 2.90 (Total Current Assets 11.20b / Total Current Liabilities 3.86b)
Debt / Equity = 0.21 (Debt 3.88b / totalStockholderEquity, last quarter 18.67b)
Debt / EBITDA = -0.25 (Net Debt -1.21b / EBITDA 4.83b)
Debt / FCF = -0.38 (Net Debt -1.21b / FCF TTM 3.19b)
Total Stockholder Equity = 17.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.24% (Net Income 3.95b / Total Assets 26.14b)
RoE = 22.70% (Net Income TTM 3.95b / Total Stockholder Equity 17.41b)
RoCE = 23.77% (EBIT 4.62b / Capital Employed (Equity 17.41b + L.T.Debt 2.03b))
RoIC = 23.76% (NOPAT 4.14b / Invested Capital 17.41b)
WACC = 7.43% (E(113.01b)/V(116.89b) * Re(7.68%) + D(3.88b)/V(116.89b) * Rd(0.08%) * (1-Tc(0.11)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -0.92%
[DCF] Terminal Value 73.41% ; FCFF base≈3.19b ; Y1≈2.10b ; Y5≈958.9m
[DCF] Fair Price = 88.24 (EV 21.24b - Net Debt -1.21b = Equity 22.44b / Shares 254.4m; r=7.43% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -1.46 | EPS CAGR: 9.99% | SUE: -0.02 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 12.18% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-06-30): EPS=4.73 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=+0 | Analysts=21
EPS current Year (2026-12-31): EPS=19.15 | Chg7d=-0.013 | Chg30d=-0.045 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+8.6%
EPS next Year (2027-12-31): EPS=21.86 | Chg7d=-0.091 | Chg30d=-0.036 | Revisions Net=-1 | Growth EPS=+14.1% | Growth Revenue=+10.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +4.1% (Analyst 8.5% - Implied 4.5%)

External Resources

Dataroma Stockcircle